A multi-center single arm phase II study to evaluate the safety and efficacy of genetically engineered autologous cells expressing anti-CD20 and anti-CD19 specific chimeric antigen receptor in subjects with relapsed and/or refractory diffuse lg Bcell

Administered By

Awarded By

Contributors

Start/End

  • February 8, 2022 - January 31, 2027